Galderma's nemolizumab shows sustained itch relief in children with atopic dermatitis in Phase II study
Galderma announced Phase II results showing nemolizumab improved itch, sleep disturbance and quality of life in children with moderate-to-severe atopic dermatitis. Benefits in children aged 2 to 11 lasted through one year of treatment; nemolizumab was well tolerated, with no new safety signals. Results will be presente